Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-mesothelin-7×19 CAR-T cells
- Development stage
- Unknown
- Lead developer
- 华东师范大学
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intratumoral, Intravenous, Arterial (e.g., Hepatic Artery)
01
Overview
Anti-mesothelin-7×19 CAR-T cells are autologous chimeric antigen receptor (CAR)-T cells genetically engineered to express a CAR targeting mesothelin (MSLN), a tumor-associated antigen frequently overexpressed on various solid tumors. These T cells are further modified to secrete interleukin-7 (IL-7) and CCL19 (7×19), two factors intended to enhance T-cell migration, infiltration, and persistence within the tumor microenvironment. The IL-7 and CCL19 are linked via a 2A peptide and co-expressed using a dual lentiviral vector system. Preclinical and early clinical studies indicate superior expansion, migration, and antitumor activity compared to conventional anti-mesothelin CAR-T cells, especially in pancreatic carcinoma, hepatocellular carcinoma, and ovarian carcinoma. A phase 1 clinical trial has been conducted (e.g., NCT03198546) with promising responses noted in solid tumor patients expressing mesothelin[1].
- Other names
- anti-MSLN-7×19 CAR-T cells
02
Targets
Mesothelin
Beyond the preview
Go deeper on anti-mesothelin-7×19 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-mesothelin-7×19 CAR-T cells.